Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: GlobalData
Provider: Sadif Analytics Prime
Provider: Sadif Analytics Prime

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Stallergenes SA Announces FDA Acceptance For Review Of BLA For Oralair

Monday, 18 Feb 2013 02:00am EST 

Stallergenes SA announced that FDA has accepted for review Biologics License Application (BLA) for Oralair, five-grass pollen extract allergen immunotherapy (AIT) sublingual tablet. 

Company Quote

-0.5 -0.98%
24 Oct 2014